^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ADI-001

    i
    Other names: ADI-001, ADI001, ADI 001
    Company:
    Adicet Bio
    Drug class:
    γδ TCR modulator, CD20-targeted CAR-T immunotherapy
    Related drugs:
    8ms
    A Phase 1 Study of ADI-001 in Lupus Nephritis (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Adicet Bio, Inc
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • ADI-001
    9ms
    GLEAN-1: A Phase 1 Study of ADI-001 in B Cell Malignancies (clinicaltrials.gov)
    P1, N=78, Recruiting, Adicet Bio, Inc | Trial completion date: Mar 2024 --> Dec 2027 | Trial primary completion date: Mar 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • ADI-001
    1year
    Expansion, Persistence and Pharmacodynamic Profile of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma Delta T Cell Therapy, in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (ASH 2023)
    ADI-001 Cmax and D28 persistent exposure were comparable to, or exceeded, those demonstrated by alternative allogeneic CAR T therapies and approved autologous CD19 CAR T therapies. Favorable clinical responses were also associated with higher mean and median peak of ADI-001 cells.
    Clinical • PK/PD data
    |
    IL15 (Interleukin 15)
    |
    ADI-001
    3years
    A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2 (ASH 2021)
    The secondary objectives for Parts 1, 2 and 3 include PK, immunogenicity, and antitumor activity of ADI-001 monotherapy or in combination with IL-2. This study is currently enrolling in 4 U.S. sites (NCT04735471).
    Clinical • P1 data • IO biomarker
    |
    CD19 (CD19 Molecule) • IL2 (Interleukin 2)
    |
    CD20 negative
    |
    ADI-001